Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease

Bram Verstockt(Universitair Ziekenhuis Leuven), Christine Breynaert(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Gert Van Assche(KU Leuven), Jonathan Cremer(KU Leuven), Clémentine Perrier(KU Leuven), Gert De Hertogh(KU Leuven), Brecht Creyns(KU Leuven), Jan Ceuppens
Frontiers in Immunology
December 18, 2018
10.3389/fimmu.2018.02983
Cited by 24

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k